A B S T R A C T Factor V must be converted to Factor Va in order to bind to a high affinity platelet surface site and participate in prothrombin activation. Osterud et al. (10) presented data that suggested that human platelets contain an activated form of Factor V and a Factor V activator. We find that the Factor V released when platelets are disrupted by freezing and thawing or sonication is activated 3-to 10-fold by thrombin as determined by coagulation assay and is therefore stored as the relatively inactive procofactor rather than in the active form Factor Va.
INTRODUCTION
Prothrombin activation requires Factors Xa, Va, and calcium ions. Results from our laboratory indicate that prothrombin activation occurs on the platelet surface (200-300 sites/cell) (1) (2) (3) (4) (5) (6) . In addition to being present in plasma, coagulation Factor V is present in platelets localized in the a-granules (7) (8) (9) . Platelet Factor V can be released by a variety of agents that stimulate platelet secretion (6, 8, 9) and once activated to Factor Va, can serve to promote Factor Xa binding to platelets (6) . Small amounts of thrombin are formed early in hemostasis (11, 12) and Osterud et al. (10) suggested that this might result from activation of Factor V by platelets. They performed experiments that suggested that platelets contain a Factor V activator distinct from thrombin as well as an activated form of Factor V. In contrast to these results we have found that the relatively small amounts of Factor V activity released from platelets after stimulation with arachidonic acid or calcium ionophore A23187 can be activated from 10-to 20-fold by treatment with thrombin (5) . Similarly Chesney et al. (8) and Vicic et al. (9) reported that Factor V activity released by ADP or collagen was activated when exposed to thrombin. In other experiments, Giles et al. (13) concluded that the apparent "V activator-like" activity observed in frozen and thawed platelets is due to the provision of a potent source of phospholipid rather than direct activation of Factor V.
Factor V as isolated from both bovine (14-16) and human (16) (17) (18) plasma is a relatively inactive pro-cofactor with M, = 330,000. Treatment with catalytic amounts of thrombin or an enzyme isolated from Russell's viper venom (RVV-V)' results in limited and specific proteolysis of the Factor V molecule, which correlates with a 10-to 80-fold increase in activity as measured by coagulation assay. The activity of Factor V in a coagulation assay appears to be due in part to the conversion of small amounts of the pro-cofactor to the active form during the assay, but also may be due to contaminating Factor Va (6) . Thus, assessments of the exact amounts of Factor V and Va in a sample based on coagulation assay is impossible because both Factor V and Va contribute to the measurement to an unknown degree.
In the present study we have extended the observation of Osterud et al. (10) by comparing the effects of thrombin, RVV-V, and platelet lysates on the activity and structure of purified coagulation Factor V. We find that the soluble fraction of platelets contain a protease that can partially activate purified Factor V and that the pattern of proteolysis is different from that observed with thrombin or RVV-V. Whether or not this platelet protease serves to activate Factor V before thrombin formation during normal hemostasis remains to be determined.
METHODS
The preparation and assay of human prothrombin, thrombin, Factor Xa, Factor V, and fibrinogen have been described (2, 3, 17) . Thrombin was assayed using U. S. standard thrombin lot J. Dansyl arginine-4-ethylpiperidine amide (DAPA) was synthesized from dansyl arginine (Pierce Chemical Co., Rockford, IL) and 4-ethylpiperidine (gift of Dr. Edward Sowers, Reilly Tar-Chemical, Indianapolis, IN) by the method of Nesheim et al. (19) . IODO-GEN (1,3,4,6- diography (22) . Factor V was iodinated by the method of Fraker and Speck (23) as previously described (6, 17) . Factor V was assayed in a one-stage assay using purified human coagulation factors (17) . The assay mixtures contained 50 MA each of (a) 6.7 mg fibrinogen/ml, (b) 100 Mg prothrombin/ ml and 20 1tg rabbit brain cephalin/ml, (c) 25 ng Factor Xa/ ml, and (d) sample. All of the reagents except fibrinogen were prepared in an assay buffer composed of 0.15 M NaCl, 5 mM trisodium citrate, 20 mM Tris-HCl, pH 7.4, and 10 mg bovine serum albumin/ml. Fibrinogen was prepared in the same buffer in the absence of bovine serum albumin. The assay was initiated by the addition of 50 MAl of 0.1 M NaCl, 40 mM CaC12, and the time required for clot formation was measured using a fibrometer (Becton-Dickinson Co., Rutherford, NJ). Standard curves were constructed by assaying dilutions of human citrated plasma pooled from 23 donors. The assay had a functional range from 0.03 to 2 mU/ ml corresponding to clotting times from 280 to 75 s.
Subcellular fractionation of platelets. Washed platelets were prepared from 500 to 1,000 ml of whole blood as described (24) . The platelets were suspended in buffer containing 75 mM Tris, pH 6.4, 100 mM KCI, 12 mM sodium citrate, and were disrupted by a nitrogen decompression technique followed by fractionation on a sucrose density gradient (25) . The sucrose density gradient centrifugation was adapted for use with a SW27 rotor (Beckman Instruments, Inc., Palo Alto, CA). Ultracentrifugation was for 2 h at 1.4 X 105 g at 4°C. Nine fractions were identified by light-scattering and collected at 4°C. Particulate fractions were diluted with buffer composed of 150 mM NaCl, 20 mM Tris-HCl, pH 7.4, 5.5 mM glucose, centrifuged for 1 h at 2.0 X 105 g at 4°C, and then the pellets were suspended in the same buffer and stored at -80°C. The soluble fraction was stored in the same buffer used for platelet disruption and the pH was adjusted to 7.4 with 1.0 M NaOH or samples were dialyzed against 150 mM NaCl, 20 mM Tris-HCl, pH 7.4, 5.5 mM glucose, and 2.5 mM CaC12 buffer before experiments.
f,-Galacosidase was assayed as described by Reitman et (27) , protein by the method of Lowry et al. (28) , and results were calculated as relative specific activities (29) .
Activation of Factor V. Thrombin-activated Factor V.
was prepared by incubating Factor V (100 Mg/ml) in a solution containing 150 mM NaCl, 2.5 mM CaC12, 0.56 mM benzamidine, 5 mg/ml recrystallized bovine serum albumin, 20 (1, 5, 6) . Binding assay mixtures contained 108 platelets/ml, 150 mM NaCl, 20 mM Tris-HCl, pH 7.4, 2.5 mM CaCl2, 5.5 mM glucose, 0.1 mM DAPA, 20 ng/ml of Factor Xa, and 5 mg/ml recrystallized bovine serum albumin. DAPA was included to prevent thrombin-induced release and activation of endogenous Factor V and to block any further thrombin action due to small amounts of thrombin present in incubations containing Vat. Incubations were carried out for 20 min, the platelets were then sedimented through oil as previously described (1) . Samples of supernatants and pellets were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (21) and radioactivity was detected by autoradiography (22) or the gels were cut and radioactive spots counted in a Beckman Bio-Camma-II y-Counter.
Collagen activity as measured by coagulation assay (<0.001 U/108 platelets). When platelets were lysed by sonication or by three cycles of freezing and thawing, Factor V activity in the platelet suspensions increased to a maximum of 0.01-0.060 U/108 platelets after 20 min in six experiments. However, if the platelet suspensions were treated with thrombin immediately after cell lysis or 20 min after cell lysis Factor V activity rapidly increased 3-to 10-fold to 0.10-0.20 U/108 platelets. The total amount of Factor V activity present in thrombin-treated platelet lysates is similar to the amount released when intact platelets are treated with thrombin (5).
Activation of 1251-labeled Factor V by thrombin and RVV-V. Human Factor V is a single chain high molecular weight pro-cofactor with apparent Mr = 330,000. We have previously shown that appearance of Factor V coagulation activity correlates with a specific bond cleavage in the molecule, which produces a doublet peptide with Mr = 78,000 (17) . We analyzed the activation of 5 jig/ml '25I-labeled Factor V by the enzymes thrombin and RVV-V using polyacrylamide gel electrophoresis with sodium dodecyl sulfate as shown in Fig. 1 . The results shown here are similar to the results we obtained previously using gels stained with Coomassie Blue except that in the current experiments the Mr = 150,000 component can be visualized (17) . The '25I-labeled Factor V is rapidly cleaved by 0.2 U/ml thrombin at 22°C producing two transient high molecular weight intermediates and three radiolabeled final products with M, = 150,000, 1 10,000, and 78,000. A fourth activation product that is weakly stained with Coomassie Blue with Mr = 30,000 (6) is not radiolabeled. The fully activated Factor V had a specific activity of 2,100 U/mg protein as measured mM CaC12, 5.5 mM glucose, recrystallized and bovine serum albumin, 5 mg/ml at 22°C, was treated with thrombin (0.2 U/ml) or RVV-V (20 ytg/ml). After 300 s thrombin (0.2 U/ ml) was added to the sample that was treated with RVV-V.
At the indicated times samples were taken, mixed with an equal volume of buffer containing sodium dodecyl sulfate and 5% 2-mercaptoethanol, and boiled for 2 min. Samples contairnirng 30 ng of 1251-labeled protein were then electrophoresed on a 7.5% polyacrylamide slab gel containing sodium dodecyl sulfate with a 4% stacking gel according to Laemmli (21) . Protein was detected by autoradiography (22) .
by coagulation assay. The enzyme RVV-V cleaves Factor V at a single location to produce a high molecular weight final product and the Mr = 78,000 component.
Two other peptides with apparent M, = 160,000 and 145,000 are formed at a much slower rate than the higher molecular weight component. After 5 min at 22°C there was no longer any intact Factor V present and the preparation had the same specific activity as thrombin activated Factor Va. Upon addition of 0.2 U/ml thrombin there was no further change in coagulation activity, however the high molecular weight product produced by cleavage with RVV-V disappeared and was replaced initially by a smaller transient high molecular weight intermediate and the Mr = 110,000 final product followed later by the appearance of the Mr = 150,000 final product.
Activation of purified Factor V by a platelet protease. We tested the ability of frozen and thawed platelets isolated from a patient with congenital Factor V deficiency to activate purified Factor V. When 5 gug/ml of purified Factor V was incubated with frozen and thawed platelets at a concentration of 108/ml there was only a small increase in Factor V activity during a 20-min incubation at 22°C from 0.7 to 1.1 U. When this mixture was treated with 2 U/ml of thrombin there was a rapid ninefold increase in Factor V activity. However, when Factor V was incubated with a Factor V-deficient lysate derived from 109 platelets/ ml the specific activity of the Factor V increased from 140±30 U/mg to a maximum of 740±240 U/mg (mean±SD of three experiments). When thrombin was added to the platelet lysate-Factor V mixture after 20 min, the activity of the Factor V increased further to 1,440±280 U/mg. When the Factor V used in this experiment was activated with thrombin in the absence of platelets it had a maximum specific activity of 1,540±60 U/mg. The platelet lysate from the Factor V-deficient patient contained no detectable Factor V activity and incubation of this lysate with thrombin activated Factor Va did not increase the activity of Factor Va in our coagulation assay.
In order to study the relationship between changes in Factor V activity and proteolysis of the Factor V molecule we incubated '251-labeled Factor V with platelet lysates and analyzed samples of these mixtures by SDS polyacrylamide gel electrophoresis and autoradiography. Fig. 2 shows a time course of the incubation of 5 gg/ml of '251-labeled Factor V with 3 X 109/ml of frozen and thawed platelets from a normal donor.2 Under these conditions there is rapid cleavage of the single chain factor V molecule, which reproducibly produced radiolabeled components with apparent Mr= 105,000, 87,000, 78,000, and 65,000. The amounts of some higher molecular weight components decreased during the incubation suggesting that they are subject to further degradation. Only the component with Mr = 78,000 migrates similarly to any of the products of Factor V activation produced by thrombin or RVV-V. The peptides with molecular weights of <65,000 are not seen in any reproducible pattern. When 109/ml of frozen and thawed platelets isolated from a patient with Factor V deficiency were used in the same type of experiment, qualitatively similar results were obtained except that the rate of proteolysis of Factor V was slower. When 108/ml of sonicated platelets were used the rate of proteolysis was still slower although even under these conditions all of the single chain Factor V was degraded after 5 min of incubation (see Fig. 3 ). At this platelet concentration only trace quantities of the M, = 78,000 peptide are formed, which is consistent with the observation that only minimal activation of Factor V occurs under these conditions.
When the Factor V that had been incubated with 2 This labeled Factor V preparation is the same as that used in Fig. 2 Laemmli (21) . Protein was detected by autoradiography (22) .
frozen and thawed platelets at a concentration of 3 X 109/ml was treated with thrombin ( Fig. 2) (21) . Protein was detected by autoradiography (22) . At 20 min 2 U/ml of thrombin was added to the reaction mixture.
constant and the peptides of Mr = 105,000 and 78,000
remained.
Further characterization of the Factor V activator present in human platelets. We next attempted to determine whether or not the Factor V activating enzyme present in platelets is expressed when platelets are stimulated with thrombin (Fig. 4) . Factor V was incubated with 3 X 109/ml of frozen and thawed platelets for 20 min, which resulted in extensive proteolysis of the Factor V molecule including production of the Mr = 78,000 peptide (Fig. 4, lane 2) . The proteolysis of Factor V is not inhibited by DAPA, a specific inhibitor of thrombin (Fig. 4, lane 3) . This indicates that the activation of Factor V seen in this system is not due to trace amounts of thrombin in the platelet preparation. When Factor V was incubated with intact platelets (3 X 109/ml) (lane 4) it was not degraded, indicating that the Factor V activating enzyme is not expressed in unstimulated platelets. DAPA (93 AM) is sufficient to inhibit the activation of Factor V by 2 U/ ml.of thrombin as shown in lane 5. When intact platelets (3 X 109/ml) were stimulated with 2 U/ml of thrombin for 5 min, followed by addition of 93 uM DAPA and then Factor V, there was no cleavage of the Factor V molecule. Therefore, the Factor V activating enzyme expressed after platelet lysis is not expressed following stimulation of platelet secretion by thrombin. We estimate that this assay system using 3 X 109/ml platelets could detect the release of the platelet protease only if 4% or more had been released since the M, = 78,000 peptide was produced in only trace amounts when '25I-labeled Factor V was incubated with 108/ml of frozen and thawed platelets. We carried out similar experiments where platelets were stimulated with either calcium ionophore A23187 (10 l,M) or collagen (25 ,ug/ml) and again could detect no evidence of protease release as measured by cleavage of '251-Factor V.
Properties of platelet protease. We determined the cellular location of the platelet protease using the method of Broekman (25) (21) . Protein was detected by autoradiography (22) . tease is in the cytoplasm although it is possible that the protease is not truly cytosolic but is in some unique granule that is either very light or very fragile. The Factor V activator was not inhibited by DAPA thereby distinguishing it from thrombin. It cleaved Factor V at the same rate in the presence and absence of EGTA (1 mM) indicating that calcium ions are not required for activity (32) . Added ATP (5 mM) neither stimulated nor inhibited proteolysis therebv distinguishing it from ATP-dependent proteases (34) (35) . The Factor V activator may be a serine protease since incubation of crude platelet homogenates with 0.2 mM DFP for 5 min at room temperature prior to the addition of 'I-Factor V inhibited subsequent proteolysis bv -50%. Prior incubation with 2 mM DFP under the same conditions resulted in complete inactivation. The protease displays activity over a broad p1I range with nearly equal activity between pH values of 6-8. Activity fell sharply at pH values <4.5 and >8. Binding of platelet protease-derived Factor Va to platelets. Factor V activated by the platelet protease is designated as Vap. We incubated V, with washed intact human platelets to determine which of its components bind to platelets as shown in Fig. 5 . The 125I-Factor V preparation used in this experiment is shown in lane 1. It was activated with either thrombin (lane 2) or the platelet protease (lane 3). Thrombin-activated Factor Va designated Vat bound to platelets as shown in lane 4. Peptides of apparent Mr= 110,000 and 78,000 were found in the platelet pellet as described previously (6) . In contrast, incubation of platelet protease-activated Va with platelets designated Vap resulted in three peptides in the platelet pellet with apparent Mr = 105,000, 87,000, and 78,000. All three of these peptides are related to Factor Va since all can be displaced from platelets with an excess of unlabeled Vat as shown in Fig. 6 . When similar experiments were carried out in the absence of Factor Xa (not shown) Vap bound less well, a result similar to that obtained with Vat (6) . Without further studies it is impossible to determine the origin and yield of these peptides with certainty. However our data suggests that the Mr = 87,000 peptide contains the M, = 78,000 peptide. This is most clearly seen in Fig. 3 where thrombin treatment of platelet-protease activated Factor V results in disappearance of the 87,000 peptide with an increase in the 78,000-dalton moiety. This apparent precursor product relationship was seen in many experiments not shown. It is also reasonable to assume that the Mr = 105,000 peptide is a slightly smaller version of the 1 10,000-dalton peptide found by thrombin. Using these assumptions we determined the specific activity and yield of the various peptides in the following manner. We sliced the polyacrylamide gels and counted the various peptides from the experiment, shown in Fig. 6 . We assumed that thrombin cleaved Factor V completely producing 1 mol each of Mr= 110,000 peptide and Mr = 78,000 peptide. The specific activity of the peptides was found to be 296 cpm/ng, 110,000-dalton peptide, and 437 cpm/ng of 78,000-dalton peptide. The amount of each peptide bound to platelets specifically was determined by subtracting the counts bound in the presence of 14 jig/ml unlabeled Vat (Fig. 6) 
DISCUSSION
Platelets possess Factor V in a-granules released after stimulation of platelet secretion or following platelet lysis (5, (7) (8) (9) (10) . This molecule has not been isolated although it seems likely to be similar if not identical to the Factor V molecule present in plasma, since both activities are deficient in congenital Factor V deficiency (3) and since Factor V inhibitor proteins derived from patients with acquired Factor V deficiency inactivate both molecules (3). Factor V isolated from human plasma is a relatively inactive procofactor composed of a single polypeptide chain with apparent Mr = 330,000 (16) (17) (18) . Plasma Factor V is converted to the active form Factor Va through limited and specific proteolysis of the molecule. In human Factor V the appearance of coagulation activity correlates with a cleavage that produces a peptide with M, = 78,000 (16, 17) . This peptide is a component of Factor Va, because we have shown that when thrombin-activated Factor Va is incubated with platelets only the Mr = 78,000 and Mr = 110,000 components bind to the platelet surface and promote prothrombin activation (6) . Esmon (15) has isolated Mr = 110,000 and 73,000 components of thrombin activated bovine Factor Va and has shown that while neither peptide had Factor V activity alone, the two peptides mixed together in the presence of calcium ions regenerated complete activity as measured in a coagulation assay. Together these results suggest that the Mr = 78,000 peptide does not itself possess Factor Va activity, but rather that this peptide is a subunit of Factor Va.
Osterud et al. (10) have proposed that platelets contain an enzyme that activates Factor V and that the Factor V released from platelets is already activated. Both Osterud et al. (10) and Vicic et al. (9) found that the Factor V activity released after platelet lysis was not activated upon subsequent treatment with thrombin. In contrast, we have found that the Factor V activity expressed following platelet lysis can be activated by treatment with thrombin. It is not clear why our results differ from those obtained in other laboratories, although we have excluded the possibility that the discrepancy is due to differences in buffer composition (data not shown). Our results suggest that most if not all of the Factor V present in platelets is stored in the pro-cofactor form and that conversion to Factor Va occurs when it is exposed to a Factor V activator.
In agreement with Osterud et al. (10) , we find that platelet lysates will activate Factor V. Thus we find that purified Factor V treated with a platelet lysate (109 platelets/ml) has a specific activity that ranges from 25 to 50% of that of thrombin-activated Factor Va. When this platelet-protease-activated Factor V was treated with thrombin, it increased to the same specific activity as thrombin activated Factor Va. The products observed when 1251-labeled Factor V is incubated with platelet lysates are different from those obtained when Factor V is activated by thrombin or RVV-V, although all three activators produce a M, = 78,000 peptide. It appears that the bond cleavage that produces the M, = 78,000 peptide is a critical event in the development of Factor V coagulation activity (16, 17 Three polypeptides derived from the platelet protease activated Factor V bind to platelets and are displaced by thrombin-activated Factor Va. These peptides of Mr = 105,000, 87,000, and 78,000 therefore appear to be related to Factor Va.
The physiological significance of the platelet protease is obscure. That it produces Factor Va in less than complete yield might argue against specificity of the protease. It is conceivable that in the process of release of Factor V during platelet activation, the platelet protease somehow achieves access to Factor V. Since platelets contain only 200-300 potential prothrombinase receptors/cell (3), yet contain 20 times this amount of Factor V (6, 37) it is possible that limited activation of Factor V could be physiologically significant but not detected by the current experiments. Without evidence for such physiological activation of Factor V the role of the platelet protease in hemostasis is uncertain.
